Radiodermatitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Radiodermatitis - Pipeline Review, H1 2016', provides an overview of the Radiodermatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Radiodermatitis - The report reviews pipeline therapeutics for Radiodermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Radiodermatitis therapeutics and enlists all their major and minor projects - The report assesses Radiodermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Radiodermatitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Radiodermatitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Radiodermatitis Overview 6 Therapeutics Development 7 Pipeline Products for Radiodermatitis - Overview 7 Pipeline Products for Radiodermatitis - Comparative Analysis 8 Radiodermatitis - Therapeutics under Development by Companies 9 Radiodermatitis - Therapeutics under Investigation by Universities/Institutes 10 Radiodermatitis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Radiodermatitis - Products under Development by Companies 13 Radiodermatitis - Products under Investigation by Universities/Institutes 14 Radiodermatitis - Companies Involved in Therapeutics Development 15 ProCertus BioPharm Inc. 15 Reata Pharmaceuticals, Inc. 16 SK Chemicals Co., Ltd. 17 Vida Therapeutics Inc. 18 Radiodermatitis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 omaveloxolone - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PrC-210 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 SKI-2162 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ST-266 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 VTI-1000 Series - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Radiodermatitis - Recent Pipeline Updates 37 Radiodermatitis - Dormant Projects 39 Radiodermatitis - Discontinued Products 40 Radiodermatitis - Product Development Milestones 41 Featured News & Press Releases 41 Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis 41 Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study 41 Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Researcha 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for Radiodermatitis, H1 2016 7 Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Radiodermatitis - Pipeline by ProCertus BioPharm Inc., H1 2016 15 Radiodermatitis - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 16 Radiodermatitis - Pipeline by SK Chemicals Co., Ltd., H1 2016 17 Radiodermatitis - Pipeline by Vida Therapeutics Inc., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Radiodermatitis Therapeutics - Recent Pipeline Updates, H1 2016 37 Radiodermatitis - Dormant Projects, H1 2016 39 Radiodermatitis - Discontinued Products, H1 2016 40
List of Figures
Number of Products under Development for Radiodermatitis, H1 2016 7 Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Top 10 Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Top 10 Molecule Types, H1 2016 26
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.